^
Association details:
Evidence:
Evidence Level:
Sensitive: B - Late Trials
Source:
Title:

Plasma-based tumor mutational burden (bTMB) as predictor for survival in phase III EAGLE study: Durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) after platinum failure.

Published date:
05/13/2020
Excerpt:
Pts with mutations in KMT2D, a HNSCC tumor suppressor gene, showed improved OS for D+T vs CT (HR 0.39; 95% CI 0.18–0.85).
DOI:
10.1200/JCO.2020.38.15_suppl.6511
Trial ID: